Autoimmune

TYK2

CHEMBL2148

VALIDATED

First production pipeline to combine Boltz-2 + ADMET-AI + ROBOGATE failure-boundary mapping on a single target.

ADMET Passed

6,478

Pareto Rank 1

500

CRO

3 compounds submitted

Stage

Gate B in progress

Mechanism

Allosteric JH2 pseudokinase domain inhibition (non-ATP-competitive)

Precedent

Deucravacitinib (BMS, approved 2022) · Zasocitinib (Takeda, Phase III)

Indications

Psoriasis · Rheumatoid arthritis · Crohn's disease

Milestones

2026-W09

Gate A assessment — 5 PASS · 1 MARGINAL · 2 FAIL → PIVOT

2026-W13

Top-3 compounds submitted to CRO (Eurofins Panlabs)

2026-W18

CRO IC50 readback expected (Gate B)